People living with HIV in England and Wales now have an alternative to daily oral tablets, after NICE backed NHS use of two long-acting injectable therapies developed by ViiV Healthcare and
After turning down routine NHS funding of Bristol-Myers Squibb's Inrebic for bone marrow disorder myelofibrosis earlier this year, NICE now says the drug can be made available via the Cance
NHS patients in England and Wales with drug-resistant epilepsy are in line for access to another treatment option, after NICE recommended routine use of Angelini group company Arvelle Pharm
NICE has reversed an earlier decision not to recommend NHS use of Kyowa Kirin's Poteligeo for two rare blood cancers, ending the threat of a north-south divide in access to the drug in the
Tens of thousands of people with chronic kidney disease in England could be eligible for treatment with AstraZeneca's SGLT2 inhibitor Forxiga, after NICE backed NHS use of the drug in draft
Big Health's Sleepio app for insomnia has been cautiously backed by NICE in preliminary guidance, although the cost-effectiveness agency says more data on longer-term use is needed.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.